Abstract:INTRODUCTION Fatal familial insomnia (FFI) is a serious and rare prion disease, which was first reported by Lugaresi et al. in 1986.[1] Early diagnosis of FFI might be important for early and sufficient counseling of patients and their relatives, also concerning the risk of inheritance, and potentially also for treatment studies. However, the diagnosis of FFI might be difficult because of the heterogeneity of clinical features, low sensitivity of diagnostic tests, and absence of family history. The aim of the present study was to develop a clinical scheme and diagnostic criteria for FFI based on our research and expert consensus. EPIDEMIOLOGY OF FATAL FAMILIAL INSOMNIA Up until 2016, more than hundred FFI cases from 50 families carrying the gene for FFI in the world have been reported. The majority of the cases reported were from Europe, specifically Italy, Spain, and Germany.[23] Although familial aggregation is robust in FFI, nine sporadic cases have been reported.[2] It is speculated that the annual incidence of FFI worldwide is about one out of a million people.[2] There are no gender differences among FFI patients. The mean age at onset of FFI is approximately 50 years (range, 21–62 years), and the duration of FFI ranges from 7 to 25 months.[3] In recent years, more and more FFI cases have been reported worldwide, more specifically in China. The first Chinese case was reported in a patient who emigrated from Hong Kong to Canada in 2004,[4] and the second case was reported from the Hubei province in 2005.[5] A higher number of cases have been reported since the China Creutzfeldt–Jakob disease (CJD) surveillance program was initiated in 2006. A total of 13 cases from 13 Chinese families have been documented from 2006 to 2017.[678910111213] Among Chinese patients, the age at onset ranges from 21 to 68 years. The average age at onset of FFI is similar to those reported in other countries, with a mean age of 46.5 years.[14] The clinical duration of FFI among the Chinese cases ranges from 6 to 38 months, which seems much longer than that for European patients.[15] Furthermore, it was reported that FFI is the most frequently identified genetic prion disease in China.[16] It is worth noting that more FFI cases have been reported in China than those in any other Asian regions (three cases were reported in Japan and one case in Korea),[3] suggesting a genetic susceptibility among the Han population. Because FFI is a rare disease and most information is from case reports, its prevalence and associated factors need to be clarified by more studies. ETIOLOGY AND PATHOGENESIS FFI is a genetic prion disease transmitted in an autosomal dominant pattern. It is associated with a missense GAC to AAC mutation at codon 178 of the prion protein (PRNP) gene located on chromosome 20, which leads to a substitution of asparagine for aspartic acid (D178N).[1718] This mutation is always associated with methionine at the polymorphic position 129 of the mutant allele in FFI.[19] Although highly expressed in brain tissues, the physiological function of the prion protein (PrP) remains enigmatic. The pathogenesis of FFI is considered to be due to the loss of the natural function of the PrP. This results in PrP that becomes more susceptible to transformation into an abnormal misfolded form, triggering a selective loss of neurons in the limbic thalamus and corticolimbic regions.[20] The highly selective neuronal loss is partly due to the binding of FFI toxic PrP or proteinase K-resistant prion protein (PrPres) to specific receptors, such as the limbic system-associated membrane protein (LAMP) receptor on thalamolimbic neurons.[21] Pathologically, FFI is characterized by severe and selective thalamic degeneration, especially in the mediodorsal and anterior ventral nuclei,[117] in which more than 50% of the magnocellular and parvocellular neurons are lost as observed during autopsy. In some cases, almost 80% neuronal loss was observed.[17] The other thalamic nuclei are less consistently and less severely involved. Other histopathological changes, including reactive astrogliosis in thalamic nuclei, the cerebral and cerebellar cortices, and the olives, are also found. Spongiosis of the cerebral cortex is observed in some cases, but is either moderate or sometimes absent, especially in cases with a short disease course.[20] Parchi et al.[22] reported that patients with disease duration shorter than 18 months only have minimal cortical cerebral astrogliosis and focal spongiosis in the entorhinal cortex, whereas patients with a disease duration longer than 18 months have cortical spongiosis and astrogliosis that are more widespread. Moderate atrophy of the cortex and basal ganglia has also been previously observed in FFI cases, while abnormalities are rarely detected in the spinal cord.[23] CLINICAL CHARACTERISTICS OF THE FATAL FAMILIAL INSOMNIA FFI is a hereditary autosomal dominant prion disease, which is mainly characterized by prominent sleep impairment accompanied by a series of neuropsychiatric disorders, dysautonomia, motor dysfunction, and episodes of peculiar oneiric behaviors (oneiric stupor).[24] Irregular breathing, hypnic jerks, propriospinal myoclonus at the wake-sleep transition, and quasi-purposeful limb gestures are considered to be core features of FFI. Homozygous FFI might be different from heterozygous FFI in terms of clinical severity.[17] The most prominent clinical manifestation is sleep disturbance, which includes insomnia, laryngeal stridor, sleep breath disturbance, oneiric or stuporous episodes with hallucinations and confusion, and sleep-related involuntary movements (such as hypnic jerks, restless sleep with frequent changes in body position, and twitchy nonpurposeful movement of limbs). However, FFI symptoms are variable and some FFI cases may not present with clinically significant insomnia.[2526] Rapidly progressive dementia (RPD) along with psychiatric symptoms occurs in all patients. Patients might have cognitive/amnestic deficits, spatial disorientation, and visual hallucinations. They may also display personality changes, depression, anxiety, aggressiveness, disinhibition, and listlessness.[27] The symptoms and signs of sympathetic hyperactivity (such as evening pyrexia, hypertension, increased sweating and tearing, tachycardia/tachypnea, and impotence) and somatomotor abnormalities (including pyramidal signs, myoclonus, dysarthria/dysphagia, and gait dysfunctions) occur with variable latency and worsen progressively. The prominent motor impairment is a gait dysfunction, and its severity and features may be related to duration and genotype.[28] Furthermore, husky voice was reported in 22% of FFI patients in Germany.[27] The main clinical and neurological features of FFI are summarized in Table 1.Table 1: Clinical characteristics of the FFI patientsDIAGNOSTIC STUDIES For diagnosis of FFI, the main tests with high diagnostic value include genetic analysis, brain magnetic resonance imaging (MRI), electroencephalograms (EEG), polysomnography (PSG), positron emission tomography (PET), single-photon emission tomography (SPECT), biochemical cerebrospinal fluid (CSF) analysis, and autopsy. Genetic analysis Genetically, FFI is associated with a GAC to AAC point mutation at codon 178 of PRNP resulting in the D178N substitution in combination with methionine (Met) at codon 129 in the mutated allele of PRNP (D178N-129M haplotype).[29] Brain magnetic resonance imaging Routine brain MRI (T1- and T2-weighted imaging) usually reveals nonspecific features including mild cerebral cortical atrophy and enlarged ventricles. The mean apparent diffusion coefficient value could increase in the thalamus.[30] Hyperintense signals could be detected by diffusion-weighted image (DWI) in the basal ganglia and other gray matter areas.[31] Electroencephalograms EEG usually demonstrates a diffusive excess of theta (θ) and delta (δ) frequencies. Periodic spike discharges are not found in most cases of FFI, but patients with long disease duration can transiently show periodic EEG activities in latter stages.[32] Polysomnography A key early polysomnographic sign of the disease onset is the loss of sleep spindles and K-complexes. Other polysomnographic findings include progressively shortened total sleep time, significantly reduced durations of rapid eye movement sleep and slow-wave sleep, abnormal behaviors, complex hallucinations, vivid dreams during sleep, and laryngeal sounds during sleep.[24] Positron emission tomography and single-photon emission tomography PET study typically indicated hypometabolism predominantly in the thalamus and cingulate cortex in FFI.[33] SPECT imaging showed reduced blood flow perfusion in bilateral temporal lobes, basal ganglia, and thalamus.[13] Cerebrospinal fluid analysis CSF biochemical test could be normal or show a mildly elevated protein concentration. The CSF is usually negative for 14-3-3 protein in FFI. Autopsy No FFI case involving brain biopsy case has been reported. At autopsy, severe thalamic neuronal loss and gliosis are characteristically seen in postmortem brains of FFI patients, usually without a concomitant spongiform change. The most seriously affected thalamic nuclei are the anteroventral, mediodorsal nuclei, and pulvinar.[3435] DIAGNOSIS Central clinical presentations in FFI patients can be divided into three categories [Table 1]: Cluster A – organic sleep disturbance, including insomnia, laryngeal stridor, sleep-related dyspnea, and sleep-related involuntary movements; Cluster B – RPD, with or without ataxia, pyramidal or extrapyramidal symptoms/signs, and psychiatric symptoms; and Cluster C – progressive sympathetic symptoms, including hypertension, sweating, tachycardia, irregular breathing, and dysarthria. Based on the above clinical classification, family history, and laboratory tests, we propose the following clinical diagnostic criteria algorithm for the diagnosis of FFI: (1) possible FFI, (2) probable FFI, and (3) definitive FFI. Core clinical features and possible fatal familial insomnia The organic sleep-related abnormalities (a) in addition to one or two other core features (b/c) are essential for a diagnosis of possible FFI. Organic sleep-related symptoms: Insomnia, lack of deep sleep, sleep fragmentation and reduction or loss of REM sleep, laryngeal stridor, sleep breath disturbance, and involuntary movements RPD: The presence or absence of ataxia, pyramidal or extrapyramidal symptoms or signs, and psychiatric symptoms Progressive sympathetic symptoms: Hypertension, sweating, tachycardia, and irregular breathing. Suggestive features and probable fatal familial insomnia If one or more of these suggestive features and two or more core features above are present, a diagnosis of probable FFI can be made. Positive family history of RPD and insomnia Organic insomnia, sleep-related apnea, laryngeal stridor, and involuntary movements revealed by PSG Low glucose uptake in the thalamus demonstrated by SPECT or PET imaging. Diagnostic features and definitive fatal familial insomnia If the PRNP gene test is positive, a diagnosis of definitive FFI can be confirmed. PRNP gene sequencing revealed D178N mutation with methionine polymorphism at codon 129. DIFFERENTIAL DIAGNOSIS Patients affected by CJD usually present with RPD, myoclonus, visual abnormalities, cerebellar dysfunction, pyramidal and extrapyramidal dysfunction, and akinetic mutism. DWI or fluid-attenuated inversion recovery (FLAIR) MRI shows a hyperintense signal in the caudate nucleus and putamen or at least two cortical regions. Although FFI patients may have any of these CJD symptoms, they do not fulfill the established diagnostic criteria for CJD.[181920] FFI patients are more likely to have longer disease durations, and severe insomnia and dysautonomia, and are less likely to have typical CJD-like cortical ribboning in DWI. D178N point mutation with biallelic codon 129 M on PRNP gene is the only causative mutation for FFI, while familial CJD may be caused by 22 types of point mutations, or by insertional mutations.[36] Neuropathological findings of FFI and CJD are quite different: selective thalamic gliosis and neuronal loss are core features of FFI while typical neuropathological findings of CJD include neuronal loss, gliosis, and vacuolation (or spongiform changes).[37] Gerstmann Sträussler Scheinker disease (GSS) is another prion disease that shares similar clinical manifestations with FFI. It typically presents as a subacute progressive ataxic and/or parkinsonian disorder with a later onset of cognitive impairment. The mean disease duration is around 5 years, ranging from 3 to more than 8 years. GSS has been associated with many different point mutations or insertional mutations of octapeptide repeats, and D178N has not been identified in GSS.[36] Limbic DWI or FLAIR hyperintensities can be found in up to 50% of cases.[38] Paraneoplastic and nonparaneoplastic limbic encephalitis can also present with RPD and behavior and movement disturbances. Unlike FFI, patients with paraneoplastic and nonparaneoplastic limbic encephalitis have acute/subacute onsets, and symptoms peak within days to weeks; CSF tests usually show pleocytosis and an increased protein level. The main MRI findings that allow the differentiation of encephalitis from FFI are cortical swelling, petechial hemorrhages, and patchy enhancement postcontrast agent administration in the subacute stage.[39] Antibody testing in both CSF and serum is especially crucial. CONCLUSION We attempted to establish easily applicable and reliable clinical diagnostic criteria for FFI based on our own research and the literature review. The scheme would also enable the clinical diagnosis in cases with/without available diagnostic testing. We hope that these criteria might improve the early recognition of this peculiar and rare prion disease. Financial support and sponsorship This work was supported by grants from the National Natural Science Foundation of China (No. 81470074), and the Clinical funding from Beijing Municipal Science and Technology Committee (No.Z14l107002514117). Conflicts of interest There are no conflicts of interest.

Abstract:Proteomics changes of brain tissues have been described in different neurodegenerative diseases including Alzheimer's disease and Parkinson's disease. However, the brain proteomics of human prion disease remains less understood. In the study, the proteomics patterns of cortex and cerebellum of brain tissues of sporadic Creutzfeldt-Jakob disease, fatal familial insomnia, and G114V genetic CJD were analyzed with isobaric tags for relative and absolute quantitation combined with multidimensional liquid chromatography and MS analysis, with the brains from three normal individuals as controls. Global protein profiling, significant pathway, and functional categories were analyzed. In total, 2287 proteins were identified with quantitative information both in cortex and cerebellum regions. Cerebellum tissues appeared to contain more up- and down-regulated proteins (727 proteins) than cortex regions (312 proteins) of Creutzfeldt-Jakob disease, fatal familial insomnia, and G114V genetic CJD. Viral myocarditis, Parkinson's disease, Alzheimer's disease, lysosome, oxidative phosphorylation, protein export, and drug metabolism-cytochrome P450 were the most commonly affected pathways of the three kinds of diseases. Almost coincident biological functions were identified in the brain tissues of the three diseases. In all, data here demonstrate that the brain tissues of Creutzfeldt-Jakob disease, fatal familial insomnia, and G114V genetic CJD have obvious proteomics changes at their terminal stages, which show the similarities not only among human prion diseases but also with other neurodegeneration diseases. This is the first study to provide a reference proteome map for human prion diseases and will be helpful for future studies focused on potential biomarkers for the diagnosis and therapy of human prion diseases. Proteomics changes of brain tissues have been described in different neurodegenerative diseases including Alzheimer's disease and Parkinson's disease. However, the brain proteomics of human prion disease remains less understood. In the study, the proteomics patterns of cortex and cerebellum of brain tissues of sporadic Creutzfeldt-Jakob disease, fatal familial insomnia, and G114V genetic CJD were analyzed with isobaric tags for relative and absolute quantitation combined with multidimensional liquid chromatography and MS analysis, with the brains from three normal individuals as controls. Global protein profiling, significant pathway, and functional categories were analyzed. In total, 2287 proteins were identified with quantitative information both in cortex and cerebellum regions. Cerebellum tissues appeared to contain more up- and down-regulated proteins (727 proteins) than cortex regions (312 proteins) of Creutzfeldt-Jakob disease, fatal familial insomnia, and G114V genetic CJD. Viral myocarditis, Parkinson's disease, Alzheimer's disease, lysosome, oxidative phosphorylation, protein export, and drug metabolism-cytochrome P450 were the most commonly affected pathways of the three kinds of diseases. Almost coincident biological functions were identified in the brain tissues of the three diseases. In all, data here demonstrate that the brain tissues of Creutzfeldt-Jakob disease, fatal familial insomnia, and G114V genetic CJD have obvious proteomics changes at their terminal stages, which show the similarities not only among human prion diseases but also with other neurodegeneration diseases. This is the first study to provide a reference proteome map for human prion diseases and will be helpful for future studies focused on potential biomarkers for the diagnosis and therapy of human prion diseases. Human prion diseases, also named human transmissible spongiform encephalopathies (TSEs) 1The abbreviations used are:TSEstransmissible spongiform encephalopathiesADAlzheimer's diseasePDParkinson's diseasesCJDsporadic Creutzfeldt–Jakob diseaseFFIfatal familial insomniagCJDG114V genetic CJDiCJDiatrogenic CJDvCJDvariant CJDGSSGerstmann–Sträussler–Scheinker diseaseiTRAQIsobaric tags for relative and absolute quantitationLCliquid chromatographyPrPprion proteinGOGene OntologyPSWperiodic sharp-wavesEEGelectroencephalogramMRIMagnetic resonance imagingCSFCerebrospinal fluidBCAbicinchoninic acidTEABtetraethylammonium bicarbonateSCXstrong cation exchangeHPLChigh performance liquid chromatographyMALDI-TOF/TOFmatrix-assisted laser desorption/ionization time-of-flight/time-of-flightHCDhigher collision energy dissociationCIDcollision induce dissociationNCEnormalized collision energyKEGGKyoto Encycloppedia of Genes and GenomesALSAmyotrophic lateral sclerosisTGNtrans-Golgi network. 1The abbreviations used are:TSEstransmissible spongiform encephalopathiesADAlzheimer's diseasePDParkinson's diseasesCJDsporadic Creutzfeldt–Jakob diseaseFFIfatal familial insomniagCJDG114V genetic CJDiCJDiatrogenic CJDvCJDvariant CJDGSSGerstmann–Sträussler–Scheinker diseaseiTRAQIsobaric tags for relative and absolute quantitationLCliquid chromatographyPrPprion proteinGOGene OntologyPSWperiodic sharp-wavesEEGelectroencephalogramMRIMagnetic resonance imagingCSFCerebrospinal fluidBCAbicinchoninic acidTEABtetraethylammonium bicarbonateSCXstrong cation exchangeHPLChigh performance liquid chromatographyMALDI-TOF/TOFmatrix-assisted laser desorption/ionization time-of-flight/time-of-flightHCDhigher collision energy dissociationCIDcollision induce dissociationNCEnormalized collision energyKEGGKyoto Encycloppedia of Genes and GenomesALSAmyotrophic lateral sclerosisTGNtrans-Golgi network., are fatal neurodegenerative disorders, including Kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker disease (GSS), and fatal familial insomnia (FFI). These various subtypes of human TSEs differed with each other in the aspects of clinical symptoms, neuropathology, and genetics, but all eventually undergo fatal consequence (1Liberski P.P. Historical overview of prion diseases: a view from afar.Folia Neuropathol. 2012; 50: 1-12PubMed Google Scholar). The conversion of prion protein (PrP), coded by the PRNP gene, from its cellular isoform PrPC to its pathogenic isoform PrPSc through a post-translational process is considered the etiology of these diseases (2Colby D.W. Prusiner S.B. Prions.Cold Spring Harb. Perspect. Biol. 2011; 3: a006833Crossref PubMed Scopus (400) Google Scholar). Human TSEs can be also etiologically classified as sporadic, such as sporadic CJD (sCJD), genetic or familial, such as genetic CJD (gCJD), GSS, and FFI, and acquired, such as iatrogenic CJD (iCJD) and variant CJD (vCJD). During the long-term pathogenesis of human TSEs, besides of accumulation of PrPSc in brain tissues, numerous brain proteins, which are involved in many different biological processes and pathways, have been described to be abnormally changed (3Shi Q. Jing Y.Y. Wang S.B. Chen C. Sun H. Xu Y. Gao C. Zhang J. Tian C. Guo Y. Ren K. Dong X.P. PrP octarepeats region determined the interaction with caveolin-1 and phosphorylation of caveolin-1 and Fyn.Med. Microbiol. Immunol. 2013; 202: 215-227Crossref PubMed Scopus (14) Google Scholar, 4Guo Y. Gong H.S. Zhang J. Xie W.L. Tian C. Chen C. Shi Q. Wang S.B. Xu Y. Zhang B.Y. Dong X.P. Remarkable reduction of MAP2 in the brains of scrapie-infected rodents and human prion disease possibly correlated with the increase of calpain.PLoS One. 2012; 7: e30163Crossref PubMed Scopus (25) Google Scholar, 5Gong H.S. Guo Y. Tian C. Xie W.L. Shi Q. Zhang J. Xu Y. Wang S.B. Zhang B.Y. Chen C. Liu Y. Dong X.P. Reduction of protein kinase MARK4 in the brains of experimental scrapie rodents and human prion disease correlates with deposits of PrP(Sc).Int. J. Mol. Med. 2012; 30: 569-578Crossref PubMed Scopus (7) Google Scholar). Recently, the global transcriptional profiles in the brain tissues of some kinds of human TSEs, for example, sCJD, gCJD, and FFI have been reported with the help of high throughput microarray technique (6Tian C. Liu D. Sun Q.L. Chen C. Xu Y. Wang S.B. Zhang B.Y. Chen C. Liu Y. Dong X.P. Comparative analysis of gene expression profiles between cortex and thalamus in Chinese fatal familial insomnia patients.Mol. Neurobiol. 2013; 48: 36-48Crossref PubMed Scopus (25) Google Scholar, 7Tian C. Liu D. Chen C. Xu Y. Gong H.S. Chen C. Shi Q. Zhang B.Y. Han J. Dong X.P. Global transcriptional profiling of the postmortem brain of a patient with G114V genetic Creutzfeldt-Jakob disease.Int. J. Mol. Med. 2013; 31: 676-688Crossref PubMed Scopus (15) Google Scholar). However, the global changes of proteins in the brain tissues, which are definitely important for understanding the pathogenesis of the disease and providing the clues for the disease diagnosis and therapy, remains seldom addressed. transmissible spongiform encephalopathies Alzheimer's disease Parkinson's disease sporadic Creutzfeldt–Jakob disease fatal familial insomnia G114V genetic CJD iatrogenic CJD variant CJD Gerstmann–Sträussler–Scheinker disease Isobaric tags for relative and absolute quantitation liquid chromatography prion protein Gene Ontology periodic sharp-waves electroencephalogram Magnetic resonance imaging Cerebrospinal fluid bicinchoninic acid tetraethylammonium bicarbonate strong cation exchange high performance liquid chromatography matrix-assisted laser desorption/ionization time-of-flight/time-of-flight higher collision energy dissociation collision induce dissociation normalized collision energy Kyoto Encycloppedia of Genes and Genomes Amyotrophic lateral sclerosis trans-Golgi network. transmissible spongiform encephalopathies Alzheimer's disease Parkinson's disease sporadic Creutzfeldt–Jakob disease fatal familial insomnia G114V genetic CJD iatrogenic CJD variant CJD Gerstmann–Sträussler–Scheinker disease Isobaric tags for relative and absolute quantitation liquid chromatography prion protein Gene Ontology periodic sharp-waves electroencephalogram Magnetic resonance imaging Cerebrospinal fluid bicinchoninic acid tetraethylammonium bicarbonate strong cation exchange high performance liquid chromatography matrix-assisted laser desorption/ionization time-of-flight/time-of-flight higher collision energy dissociation collision induce dissociation normalized collision energy Kyoto Encycloppedia of Genes and Genomes Amyotrophic lateral sclerosis trans-Golgi network. The rapid development of proteomics technologies in the past decade allows scientists to be able to define the global protein expression profiles in specific physical or pathological statuses, which are usually not fulfilled by conventional molecular biological technologies (8Otto A. Becher D. Schmidt F. Quantitative Proteomics in the field of Microbiology.Proteomics. 2014; 14: 547-565Crossref PubMed Scopus (57) Google Scholar). Isobaric tags for relative and absolute quantitation (iTRAQ) combined with multidimensional liquid chromatography (LC) and MS analysis is a widely accepted quantitative proteomics that allows a single MS analysis with multiple samples, leading to significant reduction of experimental errors generated from individual experiments (9Martinez-Esteso M.J. Casado-Vela J. Selles-Marchart S. Pedreno M.A. Bru-Martinez R. Differential plant proteome analysis by isobaric tags for relative and absolute quantitation (iTRAQ).Methods Mol. Biol. 2014; 1072: 155-169Crossref PubMed Scopus (16) Google Scholar). The approach allows for sample multiplexing, which can be up to eight-plex at the same time. iTRAQ is particularly powerful when applied on a subfraction of the proteome, thereby increasing the possibility of identifying less abundant proteins (10Evans C. Noirel J. Ow S.Y. Salim M. Pereira-Medrano A.G. Couto N. Pandhal J. Smith D. Pham T.K. Karunakaran E. Zou X. Biggs C.A. Wright P.C. An insight into iTRAQ: where do we stand now?.Anal. Bioanal. Chem. 2012; 404: 1011-1027Crossref PubMed Scopus (242) Google Scholar). All these advantages allow the method to reduce chemical noise and improve quantification accuracy, in addition to improving statistical analysis and augmenting data confidence. To investigate the global protein alterations in the brain tissues of human TSEs, the postmortem cortex and cerebellum tissues from Chinese patients with sCJD, FFI, and G114V gCJD were profiled with iTRAQ analysis, using normal Chinese brain tissues as control. Total 2287 proteins were identified in all of the tested brain samples. In the context of three human TSEs, 161 and 151 proteins were commonly up-regulated and down-regulated in the cortex region, whereas 348 and 379 proteins were commonly up-regulated and down-regulated in the cerebellum region, respectively. FFI had less protein changes than sCJD or G114V gCJD, both in cortex and cerebellum. The commonly impaired pathways among three human prion diseases were Parkinson's disease (PD), Alzheimer's disease (AD), oxidative phosphorylation, and drug metabolism-cytochrome P450. GO (Gene Ontology) analysis revealed that the top five affected biological functions among sCJD, FFI, and G114V gCJD were exactly the same. The similarity and dissimilarity among three human TSEs were discussed in detail. Usage of the stored human brain samples in the China CJD Surveillance System has been approved by the Research Ethics Committee of National Institute for Viral Disease Control and Prevention, China CDC. Human cortex and cerebellum samples collected from the patients with definitely diagnosed sCJD, FFI, or G114V gCJD were enrolled in this study. Meanwhile, the brain tissues from three Chinese individuals that died from accidents were used as normal controls including a 50 year-old man, a 63 year-old man, and a 42-year-old woman. All of them did not have a history of neurological symptoms and chronic disease. The sCJD patient was an 80-year-old man with progressive disturbance of consciousness. One month later, he developed obvious akinetic mutism and inactivity, and subsequently many other symptoms appeared such as alalia, apathy, drowsiness, and pyramidal symptoms. Typical periodic sharp-waves (PSW) were detected in electroencephalogram (EEG). Magnetic resonance imaging (MRI) did not reveal a specific abnormality. Cerebrospinal fluid (CSF) 14–3-3 protein was not performed. The patient died 13 months after onset. Neuropathological assays revealed extensive spongiform degeneration and PrPSc deposits. Western blot identified type I PrPSc in brain tissues. PRNP sequencing analysis did not find any nucleotide exchange. Polymorphism of codon 129 was Met/Met homology. The clinical, genetic, neuropathological, and PrPSc molecular features of three cases of FFI (11Shi X.H. Han J. Zhang J. Shi Q. Chen J.M. Xia S.L. Xie Z.Q. Shen X.J. Shan B. Lei Y.J. Shi S. Zhou W. Zhang B.Y. Gao C. Liu Y.H. Song J. Guo Y.J. Wang D.X. Xu B.L. Dong X.P. Clinical, histopathological, and genetic studies in a family with fatal familial insomnia.Infect. Genet. Evol. 2010; 10: 292-297Crossref PubMed Scopus (30) Google Scholar, 12Shi Q. Chen C. Gao C. Tian C. Zhou W. Zhang B. Han J. Dong X.P. Clinical and familial characteristics of ten chinese patients with fatal family insomnia.Biomed. Environ. Sci. 2012; 25: 471-475PubMed Google Scholar) and one case of G114V gCJD were described in detail in our previous work (13Shi Q. Zhang B.Y. Gao C. Han J. Wang G.R. Chen C. Tian C. Dong X.P. The diversities of PrP(Sc) distributions and pathologic changes in various brain regions from a Chinese patient with G114V genetic CJD.Neuropathology. 2012; 32: 51-59Crossref PubMed Scopus (17) Google Scholar). The main clinical features of the enrolled cases were summarized in Table I.Table IComparison of the main clinical features of the five human TSE patientsCase No.GederAge at onset (y)Family historyForemost symptomsOther signs and symptomsBlood pressure (mmHg)Progressive sympathetic symptomsCSF 14-3-3EEG (PSW*)MRITime of Diagnosis after onset(m)Duration of illness (m)Excessive sweatingSalivationMinor evening pyrexiaWeight losssCJDM80NoProgressive consciousness disturbanceAlalia, apathetic, drowsiness, pyramidal system165/90NoNoNoNoND+-113FFI1M45YesSleep disturbance, sympathetic symptomsInsomnia, dysautonomia, motor Abnormalities145/95YesYesYesYesND-Nor210FFI2F26YesSleep DisturbanceInsomnia, dysautonomia, myoclonus142/98YesYesYesYesND-Nor114FFI3M55YesSleep disturbance, fidgetInsomnia, diaphoresis, hyperthermia, memory loss145/95YesYesNoYes+-Nor28G114VF47YesProgressive dementia, tiredness, lethargyDifficulty in communication, progressive dementia and emotional labilityNoNoNoNo---12.5 Open table in a new tab Brain region samples of parietal lobe and cerebellum were homogenized 1:10 in PBS buffer (137 mm NaCl, 2.7 mm KCl, 10 mm Na2HPO4, 2 mm KH2PO4, pH7.4) according to the protocol described elsewhere (14Zhang J. Chen L. Zhang B.Y. Han J. Xiao X.L. Tian H.Y. Li B.L. Gao C. Gao J.M. Zhou X.B. Ma G.P. Liu Y. Xu C.M. Dong X.P. Comparison study on clinical and neuropathological characteristics of hamsters inoculated with scrapie strain 263K in different challenging pathways.Biomed. Environ. Sci. 2004; 17: 65-78PubMed Google Scholar). Tissue debris was removed with low speed centrifugation at 2000 × g for 10 min and the supernatants were collected. The protein concentration was determined by bicinchoninic acid (BCA) method and the samples were stored at −80 °C for further study. SDS-PAGE was performed to verify the protein quality and concentration. One hundred micrograms of each protein sample was combined with different volumes of tetraethylammonium bicarbonate (TEAB) with 0.1% SDS to equal volume level followed by treatment with trypsin (3.3 μg trypsin/100 μg total protein). The proteins in TEAB were digested with trypsin at 37 °C for 24 h and then another 1 μg trypsin was added in the proteins and digested at 37 °C for another 12 h. The solvent was removed using a SpeedVac. The iTRAQ labeling procedure was performed following the manual provided in the iTRAQ labeling kit (Applied Biosystems, Foster City, CA). The digested samples were dissolved in 30 μl of 50% TEAB together with 70 μl of isoprotocol and labeled with the iTRAQ reagents according to the protocol of the eight-plex iTRAQ labeling kit, including iTRAQ 113–119 and 121. The iTRAQ-labeled products were then pooled and subjected to strong cation exchange (SCX) fractionation. The processes of protein fractionation by HPLC and protein identification by nano RP HPLC and mass spectrometry were performed at Beijing Institute of Genomics, Chinese Academy of Science, based on a fixed methodology published previously (15Chen Z. Wen B. Wang Q. Tong W. Guo J. Bai X. Zhao J. Sun Y. Tang Q. Lin Z. Lin L. Liu S. Quantitative proteomics reveals the temperature-dependent proteins encoded by a series of cluster genes in thermoanaerobacter tengcongensis.Mol. Cell. Proteomics. 2013; 12: 2266-2277Abstract Full Text Full Text PDF PubMed Scopus (42) Google Scholar). To separate the peptides, two different HPLC approaches were adopted, high-pH RP and strong cation exchange (SCX). In the high-pH RP HPLC procedure, the peptides were loaded onto a RP column (Luna C18, 4.6 mm inner diameter × 250 mm length, Phenomenex, Los Angeles, CA), and eluted by step linear elution program, 0–10 min equilibrated in 100% solution A (2% ACN and 20 mm NH4FA, pH 10), 10–15 min fast elution from 0–12% of solution B (80% ACN and 20 mm NH4FA, pH 10), 15–50 min linear elution from 12–56% of solution B; and 50–55 min washing elution from 56–80% of solution B. In the SCX HPLC procedure, the peptides were loaded onto a SCX column (Luna SCX, 4.6 mm × 250 mm, Phenomenex), and eluted by a step linear elution program, 0–10 min equilibrated in buffer A (25% ACN, 20 mm KCl, and 10 mm KH2PO4, pH 3.0), 10–15 min fast elution from 0–5% of buffer B (25% ACN, 1 m KCl, and 10 mm KH2PO4, pH3.0), 15–50 min linear elution from 5–30% of solution B; and 50–55 min washing elution from 30–80% of solution B. All the HPLC procedures were manipulated in a Prominence HPLC system with the flow rate at 1.0 ml/min and the peptides were monitored at 214 nm. The fractioned peptides were collected at one tube/min during the linear elution period. The eluted fractions were dried in a vacuum concentrator and then dissolved with 0.1% formic acid prior to reverse-phase nLC-tandem mass spectrometry. The peptide contents in the collected fractions were first evaluated by matrix-assisted laser desorption/ionization time-of-flight/time-of-flight (MALDI-TOF/TOF) MS (Bruker Daltonics, Billerica, MA), and the fractions were further pooled to average the peptide content. The eluted fractions were delivered onto a nano RP column (5-μm Hypersil C18, 75 μm × 150 mm, Thermo Fisher Scientific, Waltham, MA) mounted in a Prominence Nano HPLC system (Ultimate3000, Dionex) and were eluted with acetonitrile (ACN) gradient from 5–40% containing 0.1% formic acid, for 95 min at 400 nl/min. The elution products were directly entered Q-Exactive MS (Thermo Fisher Scientific), setting in positive ion mode and data-dependent manner with full MS scan from 350–2000 m/z, full scan resolution at 70,000, MS/MS scan resolution at 17,500. MS/MS scan with minimum signal threshold 1E+5, isolation width at 2 Da. To evaluate the performance of this mass spectrometry on the iTRAQ labeled samples, higher collision energy dissociation (HCD) for MS/MS acquisition modes was employed. To optimize the MS/MS acquisition efficiency of HCD, normalized collision energy (NCE) was systemically examined 28% and stepped 20%. The raw MS/MS data were converted into MGF format by Thermo Fisher Proteome Discoverer 1.3 (Thermo Fisher Scientific) and the exported MGF files were searched by Mascot 2.3.0 search algorithm (Matrix Science, Boston, MA) against the Uniprot_human database (the time/date of fasta file was Wed Mar 03 23:26:45 2010 and the number of sequences for taxonomy was 20,266 (Homo sapiens)) and an automatic decoy database search was performed. The parameters in Mascot were set for peptide searching, including trypsin as the digestion enzyme, cysteine carbamidomethylation as a fixed modification. iTRAQ eight-plex on the N-terminal residue, iTRAQ eight-plex on tyrosine (Y), iTRAQ eight-plex on lysine (K), Gln-Pyro-Glu (N-term Q), and oxidation on methionine (M) as variable modification. The precursor mass tolerance was set to 15 ppm for precursor ions and 20 mmu for fragment ions. Also, several parameters in Mascot were set for peptide analysis, including the number of distinct peptides assigned for each protein given as “unique” and “peptides”; the coverage of each protein assigned given as “coverage” (supplemental Table S1). The quantification measurement for each peptide and protein was illustrated as the ratio of diseased sample to normal control one, both in the cortex and cerebellum, showing as “sCJD/Nor(Cortex), FFI/Nor(Cortex), G114V/Nor(Cortex), sCJD/Nor(Cerebellum), FFI/Nor(Cerebellum), and G114V/Nor(cerebellum).” Based on the published data (15Chen Z. Wen B. Wang Q. Tong W. Guo J. Bai X. Zhao J. Sun Y. Tang Q. Lin Z. Lin L. Liu S. Quantitative proteomics reveals the temperature-dependent proteins encoded by a series of cluster genes in thermoanaerobacter tengcongensis.Mol. Cell. Proteomics. 2013; 12: 2266-2277Abstract Full Text Full Text PDF PubMed Scopus (42) Google Scholar) and standard operating procedures (SOP) for iTRAQ-based proteomics in Beijing Institute of Genomics, Chinese Academy of Science, the prerequisites to acquire the significant changed proteins between the brains of human prion diseases and normal control were set up as following. First, a qualified protein for quantitative analysis should have at least one unique peptide labeled with iTRAQ. Second, false discovery rate (FDR) <1% was adopted for all the peptides. Third, the median of unique peptides was used as analysis method for protein ratio type, correction of isotope impurities and normalization of intensity median was considered for judging the differential proteome. The proteins whose p value <0.05 were considered the believed proteins. Finally, the proteins with 1.2-fold changes (>1.20 increased or <0.83 decreased) relative to the normal control were considered as the differential expressed ones based on the published reference (16Ren Y. Hao P. Dutta B. Cheow E.S. Sim K.H. Gan C.S. Lim S.K. Sze S.K. Hypoxia modulates A431 cellular pathways association to tumor radioresistance and enhanced migration revealed by comprehensive proteomic and functional studies.Mol. Cell. Proteomics. 2013; 12: 485-498Abstract Full Text Full Text PDF PubMed Scopus (58) Google Scholar, 17Pierce A. Unwin R.D. Evans C.A. Griffiths S. Carney L. Zhang L. Jaworska E. Lee C.F. Blinco D. Okoniewski M.J. Miller C.J. Bitton D.A. Spooncer E. Whetton A.D. Eight-channel iTRAQ enables comparison of the activity of six leukemogenic tyrosine kinases.Mol. Cell. Proteomics. 2008; 7: 853-863Abstract Full Text Full Text PDF PubMed Scopus (215) Google Scholar) and the fold changes in protein abundance were defined as the median ratio of all significantly matched spectra with tag signals. Functional analysis of the data set was done using the Ingenuity GO (Gene Ontology) and Pathway Knowledge Base (Ingenuity Systems, Redwood City, CA, www.ingenuity.com). The functional analysis identified biological functions and/or diseases that were most significant to the data set. The analysis was done against the Ingenuity Knowledge Base. Fischer's exact test was used to calculate a p value determining the probability that each biological function and/or disease assigned to that data set is because of chance alone. Canonical pathway analysis identified the pathways from the Ingenuity Pathway Knowledge Base that were most significant to the data set. The significance of the association between the data set and the canonical pathways was measured (1) by the ratio of the number of proteins from the data set that map to the canonical pathway divided by the total number of proteins that map to the canonical pathway and (2) by Fisher's exact test (see above). The focus genes from the two short lists were overlaid onto a global molecular network developed from information contained in the Ingenuity Pathway Knowledge Base. This generated networks based on the connectivity of the individual proteins. At the same time, protein cluster and the assignment of differentially expressed genes were generated. The data were processed with SPSS 16.0 statistics software; descriptive data were expressed as median (range) for continuous variables and as percent for categorical variables. Analysis of continuous variables was done using Mann-Whitney U test, and that of categorical variables was compared using the Chi-square test. A mean value and standard error of multiple data points were used to represent the final result. Student's t test was used in statistical analysis of the data between two groups. To screen the potential difference in brain protein expressions among human prion diseases and normal control, stored postmortem brain tissues of the cortex and cerebellum regions of the patients with sCJD, FFI, G114V gCJD, and normal control were separately subjected into iTRAQ based proteomic study. Considering we utilized an established algorithm for analyzing iTRAQ data (15Chen Z. Wen B. Wang Q. Tong W. Guo J. Bai X. Zhao J. Sun Y. Tang Q. Lin Z. Lin L. Liu S. Quantitative proteomics reveals the temperature-dependent proteins encoded by a series of cluster genes in thermoanaerobacter tengcongensis.Mol. Cell. Proteomics. 2013; 12: 2266-2277Abstract Full Text Full Text PDF PubMed Scopus (42) Google Scholar), we did not set up the paralleled controls. Prior to the trypsin digestion, all eight brain extracts were evaluated by a SDS-PAGE, which revealed reliable protein integrity (supplemental Fig. S1A). After digestion with trypsin and labeling with iTRAQ separately, all tested samples were pooled for peptide fractionation and identification. The data of MS/MS for digested peptides searched in the Uniprot_human showed most of the digested peptides distributed at the range between 10 and 20 amino acids, reflecting the high-efficiency trypsin digestion (supplemental Fig. S1B). In total, 256,139 MS/MS spectra were achieved, among them 61,050 were matched spectra. 2287 proteins, elicited from 14,534 unique peptides were identified with quantitative information both in cortex and cerebellum brain regions and all the proteins were identified with 95% confidence interval by the Peptide Prophet Algorithm (supplemental Table S1). The annotated spectra for some selected proteins (20 most up- and down-regulated proteins in cortex and 20 in cerebellum) among 2287 identified ones were showed as supplemental Table S2. Using the standards of 1.2-, 1.5-, and 2.0-fold change, the potential differentially expressing proteins in each disease were separately counted. The exact numbers of the up- and down-regulated proteins in cortex and cerebellum tissues from the groups of sCJD, FFI, and G114V gCJD were shown in Fig. 1A. The numbers of 1.2-, 1.5-, and 2.0-fold changed proteins in cortical regions were 1178, 403, and 117 in sCJD, 878, 235, and 74 in FFI, 1314, 537 and 183 in G114V gCJD, whereas those in cerebella regions were 1412, 671, and 158 in sCJD, 1356, 622, and 221 in FFI, 1503, 765, and 316 in G114V gCJD, respectively. For exploring the potential changes in proteomic profiles among the different human prion diseases maximally, we used the proteins that were 1.2-fold increased or decreased as the differential expressing proteins in further analyses. As shown in Fig. 1A and Table II, the numbers of the changed proteins (< or > 1.2-fold change) in the cerebellum tissues of three prion diseases were significantly higher (p = 0.039) than that of the individual cortex regions. More numbers of the changed proteins were identified in the brains of G114V gCJD and sCJD regardless of cortex or cerebellum, whereas FFI contained remarkably less changed protei

Comparison of the Pathologic and Pathogenic Features in Six Different Regions of Postmortem Brains of Three Patients with Fatal Familial Insomnia

Comparative Analysis of Gene Expression Profiles Between Cortex and Thalamus in Chinese Fatal Familial Insomnia Patients

Clinical, Histopathological and Genetic Studies in A Family with Fatal Familial Insomnia

Clinical, Histopathological and Genetic Studies in a Case of Fatal Familial Insomnia

Clinical, Histopathological and Genetic Studies in a Case of Fatal Familial Insomnia with Review of the Literature.

Brain microglia were activated in sporadic CJD but almost unchanged in fatal familial insomnia and G114V genetic CJD

Fatal Familial Insomnia: Clinical Characteristics and Genetic Description

The study on clinical,brain imaging and electroencephalogram features of a patient with fatal familial insomnia and literature review

Familial Fatal Insomnia with Atypical Clinical Features in a Patient with D178N Mutation and Homozygosity for Met at Codon 129 of the Prion Protein Gene.

Analyses of the Similarity and Difference of Global Gene Expression Profiles in Cortex Regions of Three Neurodegenerative Diseases: Sporadic Creutzfeldt-Jakob Disease (scjd), Fatal Familial Insomnia (FFI), and Alzheimer’s Disease (AD)

Altered energy metabolism in Fatal Familial Insomnia cerebral organoids is associated with astrogliosis and neuronal dysfunction

Fatal familial insomnia with abnormal signals on routine MRI: a case report and literature review

Expert Consensus on Clinical Diagnostic Criteria for Fatal Familial Insomnia

Clinical Features and Mutation Analysis of PRNP Gene in Chinese Patients with Fatal Familial Insomnia

Analysis for the features of gene expression in brain tissues from fatal familial insomnia

Translatome profiling in fatal familial insomnia implicates TOR signaling in somatostatin neurons

Fatal familial insomnia presenting with agrypnia excitata and very low atonia index level: A case report and literature review

T188K-Familial Creutzfeldt–Jacob Disease, Predominant among Chinese, Has a Reactive Pattern in CSF RT-QuIC Different from D178N-Fatal Familial Insomnia and E200K-Familial CJD

[Studies on heredity rule of the first genealogy regarding fatal familial insomnia in Henan province]

Proteomics Analyses for the Global Proteins in the Brain Tissues of Different Human Prion Diseases*

The value of heart rate variability in autonomic nervous function evaluation and diagnosis of fatal familial insomnia